Insight on Some Newly Synthesized Trisubstituted Imidazolinones as VEGFR-2 Inhibitors

被引:1
|
作者
Mohamed, Manar R. [1 ]
Mahmoud, Walaa R. [1 ]
Refaey, Rana H. [2 ]
George, Riham F. [1 ]
Georgey, Hanan H. [1 ,3 ]
机构
[1] Cairo Univ, Fac Pharm, Dept Pharmaceut Chem, Cairo 11562, Egypt
[2] October Univ Modern Sci & Arts MSA, Fac Pharm, Pharmaceut Chem Dept, Giza 12411, Egypt
[3] Egyptian Chinese Univ, Fac Pharm & Drug Technol, Dept Pharmaceut Chem, Cairo 19346, Egypt
来源
ACS MEDICINAL CHEMISTRY LETTERS | 2024年 / 15卷 / 06期
关键词
Imidazolinones; Anticancer; VEGFR-2; inhibitors; Molecular dynamics; ANTICANCER EVALUATION; CARBONIC-ANHYDRASE; KINASE INHIBITORS; DERIVATIVES; SULFONAMIDE; DESIGN;
D O I
10.1021/acsmedchemlett.4c00095
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Two series of ten new 1,2,4-trisubstituted imidazolin-5-ones were synthesized and screened against MCF-7 breast cancer and A549 lung cancer cell lines to test their potential in vitro anticancer activity. The results revealed preferential activity of the tested compounds toward MCF-7 cell lines compared to A549 cell lines. The most promising ten compounds (3a, 3c, 3f, 3g, 3h, 3i, 3j, 6a, 6f, and 6i) were subjected to VEGFR-2 enzyme inhibitory activity testing to further explore their mechanism of action. The tested compounds showed remarkable enzyme inhibition in micromolar concentrations ranging from 0.07 to 0.36 mu M, compared with Sorafenib and Sunitinib with IC50 values of 0.06 and 0.12 mu M, respectively. The most promising candidate, 3j, was further evaluated for its cell cycle phases, apoptotic induction ability, as well as its antiproliferative activity and inhibitory potential for endothelial cell migration, analyzed by a cell scratch assay. Furthermore, in silico studies were also performed to identify and detect the stability of the binding poses.
引用
收藏
页码:892 / 898
页数:7
相关论文
共 50 条
  • [1] Biological and computational assessment of new synthesized nicotinamides as potential immunomodulatory VEGFR-2 inhibitors
    Yousef, Reda G.
    Elwan, Alaa
    Abdallah, Abdallah E.
    Elkady, Hazem
    Mehany, Ahmed B. M.
    Abo-Saif, Mariam Ali
    Radwan, Mohamed M.
    ElSohly, Mahmoud A.
    Ibrahim, Ibrahim M.
    Elkady, Mohamed A.
    El-Zahabi, Mohamed Ayman
    Eissa, Ibrahim H.
    JOURNAL OF MOLECULAR STRUCTURE, 2024, 1305
  • [2] Development and strategies of VEGFR-2/KDR inhibitors
    Huang, Lingyi
    Huang, Zhengui
    Bai, Zhigiang
    Xie, Rui
    Sun, Liping
    Lin, Kejiang
    FUTURE MEDICINAL CHEMISTRY, 2012, 4 (14) : 1839 - 1852
  • [3] Novel VEGFR-2 kinase inhibitors for the treatment of cancer
    Boyer, SJ
    Burke, JM
    Brennan, CR
    Brini, W
    Collibee, W
    Dixon, JA
    Dumas, J
    Ehrgott, F
    Hatoum-Mokdad, H
    Hong, ZQ
    Kluender, HC
    Lee, W
    Ma, X
    Reeves, R
    Sibley, RN
    Turner, T
    Wong, W
    Zhang, YL
    Brink, C
    Carter, C
    Chang, Y
    Chien, DS
    Cortes, C
    Elting, J
    Jones, RM
    McHugh, M
    Natrillo, A
    Polony, B
    Vincent, P
    Wilkie, D
    Webb, D
    Zhu, GC
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2505 - U2505
  • [4] Photoactivatable Caged Prodrugs of VEGFR-2 Kinase Inhibitors
    Pinchuk, Boris
    Horbert, Rebecca
    Doebber, Alexander
    Kuhl, Lydia
    Peifer, Christian
    MOLECULES, 2016, 21 (05):
  • [5] 2-Phenylquinazolin-4(3H)-one scaffold as newly designed, synthesized VEGFR-2 allosteric inhibitors with potent cytotoxicity through apoptosis
    Elrayess, Ranza
    Elgawish, Mohamed S. S.
    Nafie, Mohamed S. S.
    Ghareb, Nagat
    Yassen, Asmaa S. A.
    ARCHIV DER PHARMAZIE, 2023, 356 (06)
  • [6] Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2
    Duncton, Matthew A. J.
    Chekler, Eugene L. Piatnitski
    Katoch-Rouse, Reeti
    Sherman, Dan
    Wong, Wai C.
    Smith, Leon M., II
    Kawakami, Joel K.
    Kiselyov, Alexander S.
    Milligan, Daniel L.
    Balagtas, Chris
    Hadari, Yaron R.
    Wang, Ying
    Patel, Sheetal N.
    Rolster, Robin L.
    Tonra, James R.
    Surguladze, David
    Mitelman, Stan
    Kussie, Paul
    Bohlen, Peter
    Doody, Jacqueline F.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2009, 17 (02) : 731 - 740
  • [7] Development of thienopyridines as VEGFR-2 kinase inhibitors.
    Munchhof, MJ
    Adams, MA
    Atherton, JA
    Beebe, JS
    Casavant, JC
    Cooper, BC
    Doty, JD
    Emerson, EE
    Foster, BF
    Gant, TG
    Garshasb, SG
    Goodwin, PG
    Harriman, SH
    Higdon, CH
    Hillerman, SH
    Interi, CI
    Jani, JJ
    Knauth, LK
    Marx, MM
    Natarajan, VN
    Noe, MN
    Rossi, AR
    Savage, DS
    Shaeffer, TS
    Smolarek, TS
    Snow, SS
    Sobolov, SS
    Soderstrom, ES
    Sun, JS
    Turncliff, RT
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 225 : U197 - U197
  • [8] An Integrated Virtual Screening Approach for VEGFR-2 Inhibitors
    Zhang, Yanmin
    Yang, Shangyan
    Jiao, Yu
    Liu, Haichun
    Yuan, Haoliang
    Lu, Shuai
    Ran, Ting
    Yao, Sihui
    Ke, Zhipeng
    Xu, Jinxing
    Xiong, Xiao
    Chen, Yadong
    Lu, Tao
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2013, 53 (12) : 3163 - 3177
  • [9] Design, synthesis, and cytotoxicity screening of new synthesized imidazolidine-2-thiones as VEGFR-2 enzyme inhibitors
    Zaki, Islam
    Ramadan, Heba M. M.
    El-Sayed, El-Sherbiny H.
    Abd El-Moneim, Mohamed
    ARCHIV DER PHARMAZIE, 2020, 353 (11)
  • [10] Synthesis and antimicrobial activity of some 1,2,4-trisubstituted imidazolinones
    Shafi, P. M.
    Basheer, P. A. M.
    Jirovetz, Leopold
    ASIAN JOURNAL OF CHEMISTRY, 2006, 18 (04) : 3188 - 3190